CN4 COST-EFFECTIVENESS OF ERLOTINIB COMPARED WITH DOCETAXEL FOR THE TREATMENT OF RELAPSED NONSMALL CELL LUNG CANCER (NSCLC) IN THE UK
Nov 1, 2006, 00:00 AM
10.1016/S1098-3015(10)63206-8
https://www.valueinhealthjournal.com/article/S1098-3015(10)63206-8/fulltext
Section Title :
Section Order :
57
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63206-8&doi=10.1016/S1098-3015(10)63206-8